Quantcast

Latest Sinovac Biotech Ltd. Stories

2011-05-25 07:00:00

BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA - News), a leading provider of biopharmaceutical products in China, announced today the unblinded results of its Phase I clinical trial for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes Hand, Foot, and Mouth Disease (HFMD). The safety observation results for the EV71 vaccine for all three age groups (adult, children and infant groups) showed good safety and tolerance...

2011-05-13 05:30:00

BEIJING, May 13, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011. First Quarter 2011 Financial Highlights Sales increased 5.3% year-over-year to $4.7 million, compared to $4.4 million. Excluding H1N1 vaccine, sales rose 50% compared to the prior year period. Cash and cash equivalents totaled $91.0 million as of March...

2011-05-09 07:00:00

BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor conferences in New York City. Piper Jaffray 8th Annual China Growth Conference Sinovac is scheduled to present at 4:00 pm on Tuesday, May 17, 2011 and will be participating in one-on-one meetings...

2011-05-03 07:00:00

BEIJING, May 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2011 before market on Friday, May 13, 2011. The Company will host a conference call on Friday, May 13, 2011 at 8:00 a.m. EDT (March 13, 2011 at 8:00 pm China Standard Time) to review the Company's financial results and provide an update on recent corporate...

2011-04-22 15:19:00

BEIJING, April 22, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today it has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2010 on April 22, 2011. The Annual Report on Form 20-F is now available on www.sec.gov. The Company will provide a hard copy of its complete audited financial statements to its shareholders free of charge upon...

2011-03-31 06:30:00

BEIJING, March 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010. Business Highlights In March 2011, Sinovac reported positive preliminary Phase I clinical trial results in adults for its proprietary EV71 inactivated vaccine against hand, foot and mouth disease. Sinovac received approval from China's SFDA (State...

2011-03-25 07:00:00

BEIJING, March 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, and Ms. Helen Yang, Investor Relations Manager, are scheduled to participate in the UBS Greater China Healthcare Corporate Day. The conference will be held in Hong Kong at UBS Office from March 28th to March 29. The Sinovac team will present and participate in small group and one-on-one meetings...

2011-03-10 07:00:00

BEIJING, March 10, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes hand, foot, and mouth disease (HFMD). The preliminary Phase I results for the EV71 vaccine in adults showed a good safety profile and preliminary immunogenicity profile....

2011-03-03 07:00:00

BEIJING, March 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011. Sinovac initiated its PCV research program in 2008. The vaccine targets infants under two years old. The target population in China is estimated at 34...

2011-03-01 07:00:00

BEIJING, March 1, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Acting Chief Financial Officer, Ms. Helen Yang, Investor Relations Manager, and Ms. Chris Lee, Investor Relations, are scheduled to present at the Rodman & Renshaw Annual China Investment Conference. The conference will be held in Shanghai from March 6th to 8th. The Sinovac team will present at 11:30 am China...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related